MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial - Wikidata - wikimedia - TriplyDB

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

http://www.wikidata.org/entity/Q33614005

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Trial Watch: Adoptive cell transfer for oncological indications Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.Immune based therapy for melanoma Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Analogue peptides for the immunotherapy of human acute myeloid leukemia.Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.LAG3 (CD223) as a cancer immunotherapy target.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.Next generation immune-checkpoints for cancer therapy.Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

P2860

Q26769884-B1C79C59-F16E-4E2F-AE41-4BE24A407EC9 Q26785545-FB3C76BC-F19C-4C81-AE5E-A662DB200689 Q26996518-1FE9DE9A-D7B2-4810-AC34-2A14D48E2D87 Q28078539-6EFD042F-EC70-4E52-A51E-028F0C9EB2EF Q33814908-C866E4F1-8229-45DF-802E-4D30A2B086D7 Q33815992-A79E2933-C10F-4D2A-95F5-7BE1E14CAC3C Q36801213-FF74CF74-A599-4600-88F8-1B4367882A7B Q36876757-F6F3812A-E287-4014-A7D9-78CF7D3BA4FB Q37158481-9DC046D4-3B56-4925-B7D6-236E52CA1B91 Q38391533-BD521F66-2FE3-45C3-BAB0-27A41B44193E Q38599586-F5C9DDD9-1171-48ED-81E5-EB81433978F6 Q38837469-2BF42480-9B5B-4C79-9590-86839FE034A3 Q38948897-B1CA0968-1A4F-4CA8-B271-6AA3409FE2BB Q39160974-D6704157-94E9-4C8D-9DD4-C34E7BF4E80E Q42369857-2B2CF157-3B23-4A07-ABED-49510B9D52B8 Q47936526-3C55A571-A6A4-4789-9D81-5E390FD690A2 Q52691583-032E93E8-568C-4240-BF8A-6B82879D396A Q55174561-369DC11D-5958-42E6-A221-7C1CA1B2039A Q55383705-F336203D-73CE-45B3-ADFD-23190D2B9648 Q57486475-95EEB834-05DC-4708-BFB0-1E310BDD19BC

P2860

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

http://www.wikidata.org/entity/Q33614005

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

MART-1 peptide vaccination plu ...... on: results of a Phase I trial

@ast

MART-1 peptide vaccination plu ...... on: results of a Phase I trial

@en

type

label

MART-1 peptide vaccination plu ...... on: results of a Phase I trial

@ast

MART-1 peptide vaccination plu ...... on: results of a Phase I trial

@en

prefLabel

MART-1 peptide vaccination plu ...... on: results of a Phase I trial

@ast

MART-1 peptide vaccination plu ...... on: results of a Phase I trial

@en

P1433

Q33614005-69F9EB22-B7FA-48A0-9DAF-78DE570DECDC

P1476

Q33614005-B5E841F5-0B8D-4583-A78A-9F198067AFAA

P2093

Q33614005-06A3D648-E193-403A-9A4B-D2C48D02341B

Q33614005-1D0F9646-FBA3-409E-B7F7-796285F284F6

Q33614005-4CC49C9F-7C6B-41BC-97D2-47EACBD4D335

Q33614005-56BB41E2-11EC-4EA5-B220-16B1D830A10B

Q33614005-58684838-CDCD-4DD1-A03F-A26E19911FA8

Q33614005-638D67C2-A0B8-4F3B-AB74-51E506C32180

Q33614005-768E084F-AA00-4D76-A1C4-77878A663E76

Q33614005-924683C0-B5CD-4AAB-AC2D-6C7829FFF450

Q33614005-BCD76264-D6EE-4B52-A4CB-FDC24A8EB63E

Q33614005-E227C156-3C49-450E-95E4-233E6C3B5A1D

P2860

Q33614005-01ABC15C-3826-4E0C-A26A-8B7C4F288924

Q33614005-0FC6A9D9-A397-4E92-9453-8EA56EDB16B1

Q33614005-1188A67B-4230-42B4-B19B-47A38F322346

Q33614005-16AEC05A-1DD1-47B3-A95D-AC35679697D2

Q33614005-22315726-36E3-4A6A-A323-99745F211E08

Q33614005-26C6DE54-0796-45DA-9256-277EDCB4F37E

Q33614005-27C1F9A0-EE71-41D4-B8EE-DB4020F8631A

Q33614005-2C885720-39A4-45CC-ACB4-D6E63EFC3012

Q33614005-375D16D0-B32F-4C5E-8803-19D6A784BC48

Q33614005-3844AD1B-DC8B-4157-9A9E-D14E5C27CDB7

P2888

Q33614005-EA32B62D-7787-41DA-AB39-4C1704D2B4AA

P304

Q33614005-223F3CAF-30D6-4E70-935E-405B2EF3C629

P31

Q33614005-D778CA4F-642B-4015-A97B-CD5A30338C05

P356

Q33614005-8BB9DC84-055B-4784-BD59-A1A6AEB17F72

P478

Q33614005-99396E44-29D1-4D6D-9803-C77B8B921E67

P50

Q33614005-3C0FE0F2-1A6C-40FB-A9F9-3EB7D0ED4D1D

P577

Q33614005-DA610484-75BE-4843-9741-406EEB865FC2

P5875

Q33614005-74A77BE5-B2D8-4AAD-B48A-31CB8CCBCBE1

P6179

Q33614005-81142CCF-F57D-466F-B3EE-A9981A68AF7F

P698

Q33614005-2AE9B995-0EA7-46CD-948B-3FC31A8599FC

P921

Q33614005-4C77922E-8186-443D-9D53-4BFAD8A78923

P932

Q33614005-1ED628B7-DDF9-49F6-8D39-A21E3B9A46CE

P356

1479-5876-12-97

P1433

Journal of Translational Medicine

P1476

MART-1 peptide vaccination plu ...... on: results of a Phase I trial

@en

P2093

Athina Stravodimou

http://www.w3.org/2001/XMLSchema#string

Daniel E Speiser

http://www.w3.org/2001/XMLSchema#string

Emanuela Romano

http://www.w3.org/2001/XMLSchema#string

Frédéric Triebel

http://www.w3.org/2001/XMLSchema#string

Hélène Bichat

http://www.w3.org/2001/XMLSchema#string

Julien Laurent

http://www.w3.org/2001/XMLSchema#string

Olivier Michielin

http://www.w3.org/2001/XMLSchema#string

Pedro Romero

http://www.w3.org/2001/XMLSchema#string

Serge Leyvraz

http://www.w3.org/2001/XMLSchema#string

Verena Voelter

http://www.w3.org/2001/XMLSchema#string

P2860

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Cancer immunotherapy: moving beyond current vaccines

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

T cell exhaustion

P2888

1479-5876-12-97

P304

97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-12-97

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Alexandre Harari

P577

2014-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261607210

http://www.w3.org/2001/XMLSchema#string

P6179

1048172973

http://www.w3.org/2001/XMLSchema#string

P698

24726012

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4021605

http://www.w3.org/2001/XMLSchema#string